Upper tract urothelial carcinoma (UTUC) accounts for approximately 5–10% of all urothelial malignancies and presents several challenges in diagnosis and management. Despite advances in imaging, surgical techniques, and systemic therapies, many clinical decisions continue to rely on limited evidence, particularly when determining which patients may benefit from kidney-sparing treatment, radical surgery, or perioperative systemic therapy.
Although international guidelines provide recommendations for UTUC management, differences in clinical practice remain, especially in areas where prospective evidence is limited or conflicting. To address these challenges, an international multidisciplinary group of experts developed the IMPACT UTUC consensus, focusing on the diagnosis, staging, and treatment of non-metastatic disease.
On November 11, 2026, Nature Reviews Urology published the consensus statement titled “International multidisciplinary Delphi consensus on advanced practice in non-metastatic upper tract urothelial carcinoma (IMPACT UTUC).”
The consensus was developed by an international group of experts, including Savio Domenico Pandolfo, Roberto Contieri, M. Carmen Mir, Peter C. Black, Alexander Kutikov, and Riccardo Autorino, alongside other collaborators.
The initiative aimed to establish expert-informed recommendations covering the non-metastatic UTUC care pathway, including diagnostic evaluation, risk stratification, kidney-sparing approaches, radical nephroureterectomy (RNU), and systemic treatment.
How Was the Consensus Developed?
IMPACT UTUC used a two-round, web-based Delphi process involving an international panel of urologists and medical oncologists from Europe, the Americas, and Asia.
A total of 73 experts were invited to participate. Of these, 55 (75%) completed the first round in October 2025, while 50 (68%) participated in the second round in November 2025.
The investigators initially developed 40 statements across two main domains: diagnosis and staging, and treatment. Each statement was evaluated using a nine-point Likert scale, with consensus agreement requiring at least 70% of participants to score a statement between 7 and 9 and fewer than 15% to score it between 1 and 3.
During the first round, consensus was achieved for 24 of the 40 statements (60%). The remaining 16 statements were revised, with two split into separate statements, resulting in 18 statements evaluated in the second round. Eight additional statements reached consensus. Overall, 32 consensus statements were established, corresponding to 80% of the original 40 statements.
Diagnosis, Staging, and Risk Stratification
One of the main areas addressed by IMPACT UTUC was the identification of patients with high-risk disease. The panel agreed that high-risk features include tumour size greater than 2 cm, high-grade pathology or cytology, multifocal disease, variant histology, radiographic evidence of local invasion, and a history of radical cystectomy for bladder cancer.
For initial diagnosis and staging, CT urography was supported as the preferred imaging modality, with magnetic resonance urography considered when contrast-enhanced CT is contraindicated. Chest CT was recommended for patients with high-risk disease, while FDG-PET/CT may be considered selectively to evaluate nodal involvement or distant metastases, particularly when conventional imaging findings are inconclusive.
The experts also supported routine cystoscopy and urinary cytology in patients with suspected UTUC. However, the role of diagnostic ureteroscopy was considered more selective.
According to the consensus, ureteroscopy with biopsy should be considered when imaging and cytology do not provide sufficient information for diagnosis or risk stratification. In selected patients with clinically evident high-risk UTUC, diagnostic ureteroscopy and biopsy confirmation may be omitted, particularly when kidney-sparing management is not being considered.
Molecular and genetic assessment was another important component. The panel supported germline DNA sequencing in patients at increased risk of Lynch syndrome and recommended testing for FGFR2/3 alterations in locally advanced or node-positive UTUC. Routine FGFR2/3 testing in low-grade disease was not supported outside clinical trials evaluating targeted therapy.
Kidney-Sparing Treatment and Surgical Management
For patients with low-risk UTUC, the panel supported kidney-sparing management as the preferred first-line approach when complete endoscopic control is achievable without compromising oncological safety. Following initial endoscopic treatment, a second-look ureteroscopy within 1–3 months was recommended to assess for residual or recurrent disease.
Distal ureterectomy was also considered an appropriate kidney-sparing option for low-grade ureteral tumours and selected high-grade cases where renal preservation is essential. Frozen section analysis was encouraged during segmental or distal ureterectomy, particularly in patients with multifocal disease or concomitant carcinoma in situ.
The panel additionally supported a single intravesical instillation of chemotherapy following diagnostic or ablative ureteroscopy for low-risk UTUC to reduce the risk of bladder recurrence, although direct prospective evidence in this setting remains limited.
For patients with high-risk disease, RNU remains the standard surgical treatment. The consensus recognized open, laparoscopic, and robotic approaches as acceptable options, with minimally invasive surgery preferred when the necessary technology and expertise are available.
Other surgical recommendations included early ureteral clipping distal to the tumour during RNU and template-based lymph node dissection in patients with high-risk UTUC, with the extent of dissection determined by the location of the primary tumour.
Perioperative Systemic Therapy
The consensus also addressed systemic treatment for patients with high-risk or locally advanced UTUC. For patients with unfavourable high-risk disease, including cT2–3 tumours and/or clinically suspected nodal involvement, the panel supported considering cisplatin-based neoadjuvant chemotherapy before RNU or ureterectomy.
This approach is particularly relevant because renal function may decline after nephroureterectomy, potentially limiting eligibility for cisplatin-based treatment in the postoperative setting.
For patients who did not receive neoadjuvant chemotherapy and have advanced pathological disease (>pT2 or node-positive), the panel supported adjuvant platinum-based chemotherapy. This recommendation was informed by the phase III POUT trial, which demonstrated improved disease-free survival (DFS) with adjuvant chemotherapy compared with surveillance. At five years, DFS was 62% versus 45%, respectively (HR 0.55; 95% CI, 0.38–0.80).
The experts also agreed that adjuvant nivolumab may be offered to selected patients with advanced pathological stage who received neoadjuvant chemotherapy or who are ineligible for or decline perioperative chemotherapy.
However, the consensus acknowledged an important limitation: although CheckMate 274 demonstrated a DFS benefit with adjuvant nivolumab in the overall high-risk urothelial carcinoma population, subgroup analyses did not establish a clear benefit specifically among patients with UTUC.
For clinically node-positive disease, the panel supported upfront systemic therapy whenever feasible, followed by restaging to determine eligibility for definitive radical treatment.
Where Was Consensus Not Reached?
Despite agreement across most areas, several aspects of UTUC management remained without formal consensus. These included the routine use of additional urinary biomarkers beyond cytology, certain technical aspects of ureteroscopy, percutaneous endoscopic management, and the role of adjuvant intracavitary therapy following kidney-sparing treatment. The panel also did not reach consensus on routinely using circulating tumour DNA (ctDNA) testing after RNU to guide adjuvant treatment in patients with high-risk or advanced disease.
Although the phase III IMvigor011 trial demonstrated a benefit with ctDNA-guided adjuvant atezolizumab in patients with postoperative ctDNA-positive muscle-invasive bladder cancer, prospective evidence specifically in UTUC remains limited. Consequently, the experts considered UTUC-specific validation insufficient to support routine ctDNA-guided management. These areas where consensus was not reached reflect limitations in the available evidence and indicate where additional prospective studies are needed.
What Does This Mean for Clinical Practice?
The IMPACT UTUC initiative provides 32 expert consensus statements covering major decisions in the management of non-metastatic upper tract urothelial carcinoma, from initial diagnostic assessment to surgery and perioperative systemic therapy. The recommendations support risk-adapted diagnostic evaluation, kidney-sparing treatment for appropriately selected low-risk patients, RNU for high-risk disease, and individualized use of perioperative systemic therapy.
At the same time, the consensus identifies important evidence gaps, particularly regarding urinary biomarkers, ctDNA-guided treatment, certain kidney-sparing strategies, and the role of adjuvant immunotherapy specifically in UTUC. Importantly, these statements represent expert agreement informed by the available literature rather than new prospective clinical evidence. They are intended to complement existing international guidelines, support multidisciplinary decision-making, and help define priorities for future UTUC research.

